Skip to main content
OpenTrials
Completed

NCT Number: NCT02371785

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease

This study evaluates the performance of the CorPath 200 System to deliver guide wires and balloons to blockages in the arteries of the leg.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The CorPath 200 System is currently marketed for remotely delivering guide wires, balloons and stents to blockages in the coronary arteries. This study will evaluate the feasibility of CorPath 200 System to deliver guide wires and balloons to blockages in non-coronary arteries.

Guide wires and balloons are delivered to blockages in the lower limbs manually by doctors.If this study shows that guide wires and balloons can be safely delivered to blockages in the lower limbs, then it will be an alternative for physicians.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General Inclusion
  • At least 18 years of age;
  • Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries;
  • The subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
  • Angiographic Inclusion

Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure.

Exclusion criteria

  • General Exclusion
  • Failure/inability/unwillingness to provide informed consent;
  • Target vessel has been previously treated with bypass;
  • Has an abdominal aortic aneurysm contiguous with the iliac artery target lesion;
  • Has contraindication to anticoagulation;
  • Has bleeding or a hypercoagulability disorder;
  • Thrombocytopenia;
  • Elevated international normalized ratio (>1.5);
  • Elevated serum creatinine (≥2.5 mg/dL);
  • Active infection;
  • Contraindication to contrast; or
  • Enrolled in concurrent clinical study.
  • Angiographic Exclusion
  • Target vessel:
  • shows evidence of previous dissection or perforation, or
  • has adjacent acute thrombus;
  • Lesion is highly calcified;
  • Lesion requires use of any atherectomy device during the procedure;
  • Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.

Treatment and study plan

CorPath 200 System

Device

Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).

Primary outcomes

  1. Device Technical Success

    Time frame: Procedure

    Number of lesions for which there was technical success" as accurate and appropriate.

  2. Adverse Events

    Time frame: Procedure

    No device-related serious adverse events during the procedure.

Secondary outcomes

  1. Clinical Procedural Success

    Time frame: 24-hours

    Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure (without an unplanned switch to the manual procedure) in the absence of device-related SAE, either within twenty-four (24) hours of the procedure or prior to hospital discharge, whichever occurs first.

  2. Fluoroscopy Time

    Time frame: Procedure

    As recorded by an X-ray system utilized during the procedure.

  3. Contrast Volume

    Time frame: Procedure

    Total amount of contrast used during CorPath procedure.

  4. Total Procedure Time

    Time frame: Procedure

    Defined as the time measured from the insertion of the hemostasis sheath until procedure complete (guide catheter removed).

  5. Interventional Procedure Time

    Time frame: Procedure

    Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.

Sponsors and collaborators

Lead sponsor

Siemens Healthineers Endovascular Robotics, Inc.

Industry

Registry information

Acronym: RAPID

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 26, 2015
Registry last updated
Mar 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.